CHF5074 reduces biomarkers of neuroinflammation in patients with mild cognitive impairment: a 12-week, double-blind, placebo-controlled study.
about
Current Research Therapeutic Strategies for Alzheimer's Disease TreatmentInconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's diseaseHarnessing Cerebrospinal Fluid Biomarkers in Clinical Trials for Treating Alzheimer's and Parkinson's Diseases: Potential and ChallengesAPOE-modulated Aβ-induced neuroinflammation in Alzheimer's disease: current landscape, novel data, and future perspectiveDistinct plasma immune signatures in ME/CFS are present early in the course of illnessAdvances in recent patent and clinical trial drug development for Alzheimer's disease.Pharmacological targeting of the β-amyloid precursor protein intracellular domain.Interpreting Alzheimer's disease clinical trials in light of the effects on amyloid-β.Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases.Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease.Preclinical to phase II amyloid beta (Aβ) peptide modulators under investigation for Alzheimer's disease.Amyloid beta modulators and neuroprotection in Alzheimer's disease: a critical appraisal.Neuroprotective and Anti-Apoptotic Effects of CSP-1103 in Primary Cortical Neurons Exposed to Oxygen and Glucose DeprivationThe roles of inflammation and immune mechanisms in Alzheimer's disease.Targeting Neuroinflammation to Treat Alzheimer's Disease.CSP-1103 (CHF5074) stabilizes human transthyretin in healthy human subjects.Neuroinflammation in Alzheimer's Disease: Pleiotropic Roles for Cytokines and Neuronal Pentraxins.Alzheimer's Disease, Oligomers, and Inflammation.
P2860
Q26765530-2A5C6E6D-EAD7-4A1D-9103-79292DF51D9AQ27003841-D730DA04-6B24-419D-9697-D1136F7A0F7DQ28072061-DE685F1B-C381-44A8-8AF7-6F85E8FF7C72Q28085213-22314716-C658-4A20-A649-50C6B79B03B7Q28263550-A69961BA-FBE1-4C85-9C21-723D5C92A685Q35738142-11FE2ABB-1B45-47BC-8BD0-C740A097C348Q37693126-DDB8CDA7-3190-47FA-9A89-73E477D26A24Q38230384-529329B1-D623-4AA0-A2D0-CE19F5569FE1Q38289739-C83C0873-ABA5-48DB-98FE-715A53980B56Q38797428-185B30F1-D908-43E6-B172-DC3376E50E5EQ38864839-6C0A3C7E-776F-4015-9633-94F9C7F73852Q38994300-F4B4EF32-C80D-4E49-BE2D-83A4867063A2Q41895193-D6B8EC94-9985-40E7-AEA4-35AF5F60213EQ42656274-352E0974-425B-419E-9CB7-737A4AD7494EQ47188911-8F00F879-5492-43F6-BB8E-9E597E55C17CQ47924309-4BA9CDF6-F2EB-4BD8-8101-B74711A1C281Q49808096-66F36F72-58EB-4D0C-91BF-652ABF2B1EFFQ52644596-43205288-E733-4CE8-B5F4-ECF3B5B5E85C
P2860
CHF5074 reduces biomarkers of neuroinflammation in patients with mild cognitive impairment: a 12-week, double-blind, placebo-controlled study.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
CHF5074 reduces biomarkers of ...... ind, placebo-controlled study.
@en
CHF5074 reduces biomarkers of ...... ind, placebo-controlled study.
@nl
type
label
CHF5074 reduces biomarkers of ...... ind, placebo-controlled study.
@en
CHF5074 reduces biomarkers of ...... ind, placebo-controlled study.
@nl
prefLabel
CHF5074 reduces biomarkers of ...... ind, placebo-controlled study.
@en
CHF5074 reduces biomarkers of ...... ind, placebo-controlled study.
@nl
P2093
P50
P921
P1476
CHF5074 reduces biomarkers of ...... lind, placebo-controlled study
@en
P2093
Dottie Norris
Enrico Frigerio
Francesco Fiorentini
Gabriella Bottini
Helen Cicirello
Jaron Winston
Laura Calza
Margarita Nunez
Massimo Franceschi
P304
P356
10.2174/13892037113149990144
P577
2013-09-01T00:00:00Z